

FEB 28 2005

PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$ 0.00)

### Complete if Known

Application Number	10/070,532
Filing Date	March 7, 2002
First Named Inventor	Daniel R. Soppet
Examiner Name	C. J. Nichols
Art Unit	1647
Attorney Docket No.	PF168P3

### METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  None  Other (please identify): \_\_\_\_\_

Deposit Account Deposit Account Number: 08-3425 Deposit Account Name: Human Genome Sciences, Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below  Charge fee(s) indicated below, except for the filing fee  
 Charge any additional fee(s) or underpayment of  Credit any overpayments

### FEE CALCULATION

#### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		
	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fees Paid (\$)</u>
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

#### 2. EXCESS CLAIM FEES

##### Fee Description

Each claim over 20 (including Reissues)

<u>Small Entity</u>	
<u>Fee (\$)</u>	<u>Fee (\$)</u>

50 25

Each independent claim over 3 (including Reissues)

200 100

Multiple dependent claims

360 180

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>
23 - 45 =	x	=		<u>Fee (\$)</u> <u>Fee Paid (\$)</u>
5 - 7 =	x	=		_____

#### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
_____	- 100 =	/50 (round up to a whole number) x	=	<u>Fees Paid (\$)</u>

#### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): \_\_\_\_\_

##### SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	40,302	Telephone	(301) 610-5771
Name (Print/Type)	Kenley K. Hoover			Date	February 28, 2005

**VIA HAND DELIVERY FEBRUARY 28TH, 2005**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*FEB 28 2005  
SC58  
PATENT & TRADEMARK OFFICE*  
In re Patent Application of: Soppet et al.

Confirmation No.: 5548

Application No.: 10/070,532

Group Art Unit: 1647

Filed: March 7, 2002

Examiner: Nichols, Christopher J.

For: Human Neuropeptide Receptor

Atty. Dkt. No. PF168P3

**REPLY AND AMENDMENTS UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:

In response to the Office Action mailed November 1, 2004, please consider the following amendments and remarks. Applicant submits concurrently herewith: (a) a legible copy of page 38 of the specification as originally filed; (b) a Statement by Attorney for Applicant Regarding Permanence and Availability of Deposited Plasmids; (c) a petition for extension of time one month up to and including March 1, 2005; and (d) a Fee Transmittal, together with the appropriate fee(s).

Prior to further examination, Applicant respectfully requests entry of the following amendments.

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.
- Remarks begin on page 6 of this paper.